Literature DB >> 30903322

Celia's encephalopathy and c.974dupG in BSCL2 gene: a hidden change in a known variant.

Sofía Sánchez-Iglesias1, Melissa Crocker2, Mar O'Callaghan3, Alejandra Darling3, Angels García-Cazorla3, Rosario Domingo-Jiménez4, Ana Castro5, Antía Fernández-Pombo1,5, Álvaro Ruibal6,7, Pablo Aguiar6,7, Miguel Garrido-Pumar6,7, Antonio Rodríguez-Núñez8, Julián Álvarez-Escudero9, Rebecca J Brown10, David Araújo-Vilar11,12,13.   

Abstract

Celia's encephalopathy (progressive encephalopathy with/without lipodystrophy (PELD)) is a childhood neurodegenerative disorder with a fatal prognosis before the age of 10, due to the variant c.985C>T in the BSCL2 gene that causes a cryptic splicing site leading to skipping of exon 7. For years, different authors have reported cases of congenital generalized lipodystrophy due to the variant c.974dupG in BSCL2 associated with neurological manifestations of variable severity, although some of them clearly superimposable to PELD. To identify the molecular mechanisms responsible for these neurological alterations in two patients with c.974dupG. Clinical characterization, biochemistry, and neuroimaging studies of two girls carrying this variant. In silico analysis, PCR amplification, and BSCL2 cDNA sequencing. BSCL2-201 transcript expression, which lacks exon 7, by qPCR in fibroblasts from the index case, from a healthy child as a control and from two patients with PELD, and in leukocytes from the index case and her parents. One with a severe encephalopathy including a picture of intellectual deficiency, severe language impairment, myoclonic epilepsy, and lipodystrophy as described in PELD, dying at 9 years and 9 months of age. The other 2-year-old patient showed incipient signs of neurological involvement. In silico and cDNA sequencing studies showed that variant c.974dupG gives rise to skipping of exon 7. The expression of BSCL2-201 in fibroblasts was significantly higher in the index case than in the healthy child, although less than in the case with homozygous PELD due to c.985C>T variant. The expression of this transcript was approximately half in the healthy carrier parents of this patient. The c.974dupG variant leads to the skipping of exon 7 of the BSCL2 gene and is responsible for a variant of Celia's encephalopathy, with variable phenotypic expression.

Entities:  

Keywords:  BSCL2; Congenital generalized lipodystrophy; Cryptic splicing; Neurodegeneration; PELD

Mesh:

Substances:

Year:  2019        PMID: 30903322      PMCID: PMC7288395          DOI: 10.1007/s10048-019-00574-5

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  26 in total

1.  Phenotypes of the N88S Berardinelli-Seip congenital lipodystrophy 2 mutation.

Authors:  Michaela Auer-Grumbach; Beate Schlotter-Weigel; Hanns Lochmüller; Gertrud Strobl-Wildemann; Piet Auer-Grumbach; Renate Fischer; Hans Offenbacher; Ernst Bernhard Zwick; Tanja Robl; Gerald Hartl; Hans-Peter Hartung; Klaus Wagner; Christian Windpassinger
Journal:  Ann Neurol       Date:  2005-03       Impact factor: 10.422

2.  Complementary mutations in seipin gene in a patient with Berardinelli-Seip congenital lipodystrophy and dystonia: phenotype variability suggests multiple roles of seipin gene.

Authors:  Y-R Wu; S-I Hung; Y-C Chang; S-T Chen; Y-L Lin; W-H Chung
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-10       Impact factor: 10.154

3.  A Taiwanese boy with congenital generalized lipodystrophy caused by homozygous Ile262fs mutation in the BSCL2 gene.

Authors:  Hsiu-Hui Huang; Tai-Heng Chen; Hui-Pin Hsiao; Chia-Tsuan Huang; Cheng-Chu Wang; Ya-Huei Shiau; Mei-Chyn Chao
Journal:  Kaohsiung J Med Sci       Date:  2010-11       Impact factor: 2.744

4.  Membrane topology of the human seipin protein.

Authors:  Carolina Lundin; Rickard Nordström; Klaus Wagner; Christian Windpassinger; Helena Andersson; Gunnar von Heijne; IngMarie Nilsson
Journal:  FEBS Lett       Date:  2006-03-27       Impact factor: 4.124

5.  Reduced adipogenic gene expression in fibroblasts from a patient with type 2 congenital generalized lipodystrophy.

Authors:  B Victoria; J M Cabezas-Agrícola; B González-Méndez; G Lattanzi; R Del Coco; L Loidi; F Barreiro; C Calvo; J Lado-Abeal; D Araújo-Vilar
Journal:  Diabet Med       Date:  2010-10       Impact factor: 4.359

6.  Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy.

Authors:  C A Kim; Marc Delépine; Emilie Boutet; Haquima El Mourabit; Soazig Le Lay; Muriel Meier; Mona Nemani; Etienne Bridel; Claudia C Leite; Debora R Bertola; Robert K Semple; Stephen O'Rahilly; Isabelle Dugail; Jacqueline Capeau; Mark Lathrop; Jocelyne Magré
Journal:  J Clin Endocrinol Metab       Date:  2008-01-22       Impact factor: 5.958

Review 7.  The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

Authors:  Rebecca J Brown; David Araujo-Vilar; Pik To Cheung; David Dunger; Abhimanyu Garg; Michelle Jack; Lucy Mungai; Elif A Oral; Nivedita Patni; Kristina I Rother; Julia von Schnurbein; Ekaterina Sorkina; Takara Stanley; Corinne Vigouroux; Martin Wabitsch; Rachel Williams; Tohru Yorifuji
Journal:  J Clin Endocrinol Metab       Date:  2016-10-06       Impact factor: 5.958

Review 8.  Diagnosis and treatment of lipodystrophy: a step-by-step approach.

Authors:  D Araújo-Vilar; F Santini
Journal:  J Endocrinol Invest       Date:  2018-04-27       Impact factor: 4.256

9.  Seipin is required for converting nascent to mature lipid droplets.

Authors:  Huajin Wang; Michel Becuwe; Benjamin E Housden; Chandramohan Chitraju; Ashley J Porras; Morven M Graham; Xinran N Liu; Abdou Rachid Thiam; David B Savage; Anil K Agarwal; Abhimanyu Garg; Maria-Jesus Olarte; Qingqing Lin; Florian Fröhlich; Hans Kristian Hannibal-Bach; Srigokul Upadhyayula; Norbert Perrimon; Tomas Kirchhausen; Christer S Ejsing; Tobias C Walther; Robert V Farese
Journal:  Elife       Date:  2016-08-26       Impact factor: 8.140

10.  Whole Exome Sequencing Reveals a BSCL2 Mutation Causing Progressive Encephalopathy with Lipodystrophy (PELD) in an Iranian Pediatric Patient.

Authors:  Mohammad Reza Alaei; Saeed Talebi; Mohammad Ghofrani; Mohsen Taghizadeh; Mohammad Keramatipour
Journal:  Iran Biomed J       Date:  2016-07-25
View more
  1 in total

1.  Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report.

Authors:  Stefania Pedicelli; Luca de Palma; Caterina Pelosini; Marco Cappa
Journal:  Ital J Pediatr       Date:  2020-10-24       Impact factor: 2.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.